Skip to content

Clinical trials

Observational Glioma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glioma Phase: Observational Country / region: United States Clear all

76 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20033
20046
20051
20063
20092
20103
20113
20123
20131
20144
20154
20164
20172
20184
20195
20202
20211
20226
20234
20244
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed42
Terminated12
Recruiting9
Active, not recruiting4
Withdrawn3
Suspended2
Unknown status2
Not yet recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)8
National Institute of Neurological Disorders and Stroke (NINDS)6
M.D. Anderson Cancer Center4
Wake Forest University Health Sciences4
Mayo Clinic3
Memorial Sloan Kettering Cancer Center3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
Duke University2
University of California, San Francisco2
University of Texas Southwestern Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glioma76
Brain Neoplasms32
Glioblastoma23
Astrocytoma21
Oligodendroglioma14
Central Nervous System Neoplasms10
Ependymoma7
Neoplasms7
Medulloblastoma6
Meningioma6

Trials

Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.